Chemical process and intermediates used therein
AssigneeZeneca Limited
InventorsAndrew P. Thomas, David M. G. Martin, Stanley A. Lee, Lyn Powell
Life of this patent
Estimating the term…
Abstract
The invention provides a novel chemical process for the manufacture of certain imidazo[4,5-b]pyridine derivatives of the formula I wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula II as defined herein. Certain of the intermediates are novel and are provided as a further feature of the invention.
Claims11
A process for the manufacture of an imidazo [4,5-b]pyridine of the formula I ##STR6## or a physiologically acceptable salt thereof, wherein R.sup.1 is (1-6C)alkyl;
- R.sup.2 is hydrogen or halogeno;
- and R.sup.3 and R.sup.4 are selected from hydrogen, halogeno, (1-6C)alkyl, (1-6C)alkoxy, hydroxymethyl and hydroxy;
- which is characterised in that a compound of the formula II ##STR7## wherein P.sup.1 is an electron-deficient phenyl group or is a pyridyl or pyrimidyl group, is reacted with a base selected from an alkali metal hydroxide, (1-12C)alkanolate, (1-12C)alkanethiolate, phenolate, thiophenolate and diphenylphosphide, wherein any phenyl ring of the latter three groups may optionally bear a (1-4C)alkyl, (1-4C)alkoxy or halogeno substituent;
- whereafter:
- when a physiologically acceptable salt of a compound of formula I is required, it is obtained by reaction with the appropriate acid or base affording a physiologically acceptable ion, or by any other conventional salt formation procedure;
- and when an optically active form of a compound of formula I is required, the process is carried out with an optically active form of the starting material of formula II, or a racemic form of a compound of formula I is resolved using a conventional procedure;
- and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and P.sup.1 have any of the meanings defined above.
A process as claimed in claim i for the preparation of an imidazo[4,5-b]pyridine of the formula I selected from 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]-3H-imidazo-[4,5-b] pyridine and 2-ethyl-5,7-dimethyl-3-[(2'-(lH-tetrazol-5-yl)biphenyl-4yl)methyl]-3H-imid azo[4,5-b]pyridine), or of a physiologically acceptable salt thereof.
A compound of the formula II ##STR8## in either a racemic or optically active form;
- wherein P.sup.1 is an electron-deficient phenyl group or is a pyridyl or pyrimidyl group;
- and wherein R.sup.1 is (1-6C)alkyl;
- R.sup.2 is hydrogen or halogeno;
- and R.sup.3 and R.sup.4 are selected from hydrogen, halogeno, (1-6C) alkyl, (1-6C) alkoxy, hydroxymethyl and hydroxy.
Dependencies are inferred from the claim text.